Clinical Trial Update: Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of cyclophosphamide and rituximab followed by vaccine therapy for chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN